Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(3):155; doi:10.1093/jnci/94.3.155
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 94, No. 3, 155, February 6, 2002
© 2002 Oxford University Press

IN THIS ISSUE

All-Cause Mortality in Cancer Screening Trials

Disease-specific mortality is the most widely accepted end point in randomized cancer screening trials. The validity of this end point requires that the cause of death be accurately determined. An alternative end point, all-cause mortality, requires only that the death and the date be accurately ascertained. Black et al. (p. 167) compared disease-specific and all-cause mortality in 12 published randomized trials of cancer screening with information on both end points. They found major inconsistencies in the results for these end points in seven of the 12 . . . [Full Text of this Article]

Platinum-Based Therapy in Elderly Lung Cancer Patients

Lung Cancer After Treatment for Hodgkin’s Disease

Cost-Effectiveness of Cervical Cancer Screening Policies

ATM Mutations in Breast Cancer Families

Allelic Imbalances in Bladder Cancer